From JPMA On assuming the position of Chairman
1. changes in the environment surrounding the pharmaceutical industry
Today, various changes are rapidly progressing in the environment surrounding us. In the pharmaceutical industry as well, the structure of markets and industries, sources of competitiveness, and means of business activities are changing dramatically. The industry used to be dominated by "vertical integration," in which a single company produced the entire value chain from R&D to sales in-house, but it is undergoing a major shift to a "horizontal division of labor," in which multiple companies collaborate on each stage of the value chain.
We must also keep in mind that the competitiveness of pharmaceutical companies is changing from scientific and sales capabilities to a variety of other factors, such as highly independent corporate governance, human rights, diversity, and SDGs (Sustainable Development Goals).
The pharmaceutical industry is now being called upon to transform itself in order to meet the increasingly diverse and sophisticated healthcare needs on a global scale.
Japan Pharmaceutical Manufacturers Association
Yasushi Okada, Chairman
Toward building the foundation of the pharmaceutical industry
The spread of new coronavirus infection has revealed the fragility of Japan's vaccine development infrastructure. It is essential to strengthen Japan's drug discovery capabilities not only to respond to a possible future pandemic, but also to meet the unmet medical needs that still exist today by creating innovative new drugs to protect the lives and health of the Japanese people.
To this end, Japan needs to create a life science cluster where entrepreneurial minds can gather, venture companies can start up cutting-edge research, and various research institutes can gather, develop a Japanese big data infrastructure to promote digital transformation (DX), and evaluate the innovations generated appropriately. It is important to build a pharmaceutical industry infrastructure, or healthcare ecosystem, in Japan that is centered on these three elements.
We will do our utmost to ensure that the public understands that the pharmaceutical industry is an indispensable and important industry for creating innovative innovations, extending the healthy life expectancy of the Japanese people, and contributing to Japan's economic growth, and that it will receive tremendous support. We will also actively engage in discussions with the many stakeholders in the industry and work toward the formation of an internationally competitive life science cluster in Japan, the development of a big data infrastructure, and the establishment of a NHI drug price system that appropriately evaluates innovation.
(From the May 20 press conference by the head of the Pharmaceutical Manufacturers Association of Japan)
Japan Pharmaceutical Manufacturers Association (JPMA)
Japan Pharmaceutical Manufacturers Association (JPMA)
The Pharmaceutical Manufacturers Association of Japan (PMAJ), founded in 1968, is an association of R&D-oriented pharmaceutical companies that aim to contribute to the improvement of health and welfare of people around the world through research and development of ethical drugs for use in hospitals, clinics, and other medical institutions.
The organization is dedicated to promoting a deeper understanding of pharmaceuticals and providing policy recommendations for the sound development of the pharmaceutical industry, with the aim of realizing patient-participatory medicine.
As a member organization of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the Pharmaceutical Manufacturers Association of Japan (PAPJ) is engaged in global activities in cooperation with other organizations to address issues related to medicine and pharmaceuticals around the world.
Aiming to contribute to society through the development of new drugs Japan Pharmaceutical Manufacturers Association